Sage Therapeutics clinical trials
Acquired by Supernus Pharmaceuticals, Inc., Jul 31, 2025 · source ↗
The registry lists 6 studies whose lead sponsor is Sage Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 1, 2025.
Before and after it joined Supernus Pharmaceuticals, Inc.
- First submitted before Sage Therapeutics became part of Supernus Pharmaceuticals, Inc.
- 6
- First submitted after Sage Therapeutics became part of Supernus Pharmaceuticals, Inc.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Sage Therapeutics6 studies
Something wrong with this grouping? Tell us on the Supernus Pharmaceuticals, Inc. page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Supernus Pharmaceuticals, Inc. studies →
- A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential TremorTerminatedNCT05366751Phase 2/3
Sponsor listed in the registry: Sage Therapeutics · First submitted before Sage Therapeutics became part of Supernus Pharmaceuticals, Inc.
- Study to Evaluate SAGE-324 in Participants With Essential TremorCompletedNCT05173012Phase 2
Sponsor listed in the registry: Sage Therapeutics · First submitted before Sage Therapeutics became part of Supernus Pharmaceuticals, Inc.
- A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential TremorCompletedNCT04305275Phase 2
Sponsor listed in the registry: Sage Therapeutics · First submitted before Sage Therapeutics became part of Supernus Pharmaceuticals, Inc.
- A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)TerminatedNCT04537806Phase 3
Sponsor listed in the registry: Sage Therapeutics · First submitted before Sage Therapeutics became part of Supernus Pharmaceuticals, Inc.
- Evaluate SAGE-547 in Participants With Essential TremorCompletedNCT02277106Phase 2
Sponsor listed in the registry: Sage Therapeutics · First submitted before Sage Therapeutics became part of Supernus Pharmaceuticals, Inc.
- A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)WithdrawnNCT04273191Phase 4
Sponsor listed in the registry: Sage Therapeutics · First submitted before Sage Therapeutics became part of Supernus Pharmaceuticals, Inc.